Yu H - Search Results

1

Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity.

Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau F, Yu H, Pardoll DM, Drake CG. Harris TJ, et al. Among authors: yu h. J Immunol. 2007 Oct 1;179(7):4313-7. doi: 10.4049/jimmunol.179.7.4313. J Immunol. 2007. PMID: 17878325

2

Advances in gene therapy for malignant melanoma.

Sotomayor MG, Yu H, Antonia S, Sotomayor EM, Pardoll DM. Sotomayor MG, et al. Among authors: yu h. Cancer Control. 2002 Jan-Feb;9(1):39-48. doi: 10.1177/107327480200900106. Cancer Control. 2002. PMID: 11907465 Free article. Review.

3

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Niu G, et al. Among authors: yu h. Oncogene. 2002 Mar 27;21(13):2000-8. doi: 10.1038/sj.onc.1205260. Oncogene. 2002. PMID: 11960372

4

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Wang T, et al. Among authors: yu h. Nat Med. 2004 Jan;10(1):48-54. doi: 10.1038/nm976. Epub 2003 Dec 21. Nat Med. 2004. PMID: 14702634 Free article.

5

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A. Ravi R, et al. Among authors: yu h. Cancer Res. 2004 Dec 15;64(24):9105-14. doi: 10.1158/0008-5472.CAN-04-2488. Cancer Res. 2004. PMID: 15604280

6

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.

Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H. Burdelya L, et al. Among authors: yu h. J Immunol. 2005 Apr 1;174(7):3925-31. doi: 10.4049/jimmunol.174.7.3925. J Immunol. 2005. PMID: 15778348 Free PMC article.

7

Targeting STAT3 affects melanoma on multiple fronts.

Kortylewski M, Jove R, Yu H. Kortylewski M, et al. Among authors: yu h. Cancer Metastasis Rev. 2005 Jun;24(2):315-27. doi: 10.1007/s10555-005-1580-1. Cancer Metastasis Rev. 2005. PMID: 15986140 Review.

8

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways.

Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H. Xu Q, et al. Among authors: yu h. Oncogene. 2005 Aug 25;24(36):5552-60. doi: 10.1038/sj.onc.1208719. Oncogene. 2005. PMID: 16007214

9

Role of Stat3 in regulating p53 expression and function.

Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H. Niu G, et al. Among authors: yu h. Mol Cell Biol. 2005 Sep;25(17):7432-40. doi: 10.1128/MCB.25.17.7432-7440.2005. Mol Cell Biol. 2005. PMID: 16107692 Free PMC article.

10

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, Jove R, Pardoll D, Yu H. Kortylewski M, et al. Among authors: yu h. Nat Med. 2005 Dec;11(12):1314-21. doi: 10.1038/nm1325. Epub 2005 Nov 20. Nat Med. 2005. PMID: 16288283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38,823 results

Search Page

Filters